TG Therapeutics Financial Statements
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics revenue and earnings
In fiscal 2025, TG Therapeutics generated $616.3 million in revenue, up 87.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $447.2 million (+1812.4% year over year), for a net margin of 72.6% versus a median of -5204.1% in the prior 5 years. Gross margin was 83.7% (down from 88.3%) and operating margin 20.0%.
Diluted earnings per share came in at $2.77, up from $0.15. Over the last 5 fiscal years, TGTX's revenue has grown at a 426.7% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 616.29M | 329.00M | 233.66M | 2.79M | 6.69M | 152.00K | 152.00K | 152.00K | 152.00K | 152.00K |
| Revenue growth (YoY) | +87.32% | +40.80% | +8290.02% | -58.36% | +4300.66% | 0.00% | 0.00% | 0.00% | 0.00% | — |
| Cost of Revenue | 100.71M | 38.49M | 14.13M | 265.00K | 790.00K | — | — | — | — | — |
| Gross Profit | 515.57M | 290.52M | 219.53M | 2.52M | 5.90M | — | — | — | — | — |
| Operating Expenses | 392.25M | 248.59M | 198.90M | 195.62M | 351.46M | 273.75M | 169.21M | 174.55M | 118.86M | 79.12M |
| Research & Development | 160.22M | 94.29M | 76.19M | 125.35M | 222.58M | 165.90M | 154.18M | 159.39M | 102.53M | 69.23M |
| Selling, General & Admin | 232.03M | 154.30M | 122.71M | 95.48M | 128.09M | 107.85M | 15.03M | — | — | — |
| Operating Income | 123.32M | 41.93M | 20.63M | -218.32M | -344.77M | -273.59M | -169.06M | -174.40M | -118.71M | -78.97M |
| Interest Expense | 26.73M | 24.03M | 12.62M | 10.19M | 5.64M | 6.33M | 5.29M | 877.00K | 845.00K | — |
| Other Income (Expense) | -15.93M | -16.34M | -7.57M | -5.50M | -3.33M | -5.79M | -3.82M | 918.00K | 236.00K | 716.00K |
| Pretax Income | 107.39M | 25.59M | 13.06M | -223.81M | -348.10M | -279.38K | -172.87K | -173.48K | -118.48K | -78.25M |
| Income Tax | -339.79M | 2.21M | 390.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 447.18M | 23.38M | 12.67M | -223.81M | -348.10M | -279.38M | -172.87M | -173.48M | -118.48M | -78.25M |
| Net Income growth (YoY) | +1812.41% | +84.52% | — | — | — | — | — | — | — | — |
| EPS (Basic) | 3.10 | 0.16 | 0.09 | -1.65 | -2.63 | -2.42 | -1.96 | -2.30 | -1.91 | -1.60 |
| EPS (Diluted) | 2.77 | 0.15 | 0.09 | -1.65 | -2.63 | -2.42 | -1.96 | -2.30 | -1.91 | -1.60 |
| Shares Outstanding (Basic) | 144.32M | 145.32M | 141.96M | 135.41M | 132.22M | 115.33M | 88.37M | 75.47M | 62.07M | 49.04M |
| Shares Outstanding (Diluted) | 161.41M | 160.34M | 148.51M | 135.41M | 132.22M | 115.33M | 88.37M | 75.47M | 62.07M | 49.04M |
| EBITDA | 123.38M | 42.00M | 20.84M | -218.01M | -344.49M | -273.44M | -168.96M | -174.31M | -118.63M | -78.91M |
| Gross Margin | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% | — | — | — | — | — |
| Operating Margin | 20.01% | 12.74% | 8.83% | -7838.99% | -5154.28% | -179996.05% | -111220.39% | -114736.84% | -78100.00% | -51953.29% |
| Net Margin | 72.56% | 7.11% | 5.42% | -8036.34% | -5204.08% | -183803.29% | -113730.92% | -114132.89% | -77944.74% | -51482.24% |
This table shows 10 annual periods of TG Therapeutics's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TGTX's reporting calendar. What is a income statement?